Projects per year
Personal profile
Area of Expertise
My laboratory is interested in developing and characterizing safe and effective drugs that can be used for the treatment of individuals afflicted with Parkinson’s disease, Alzheimer’s disease, schizophrenia, Tourette syndrome, and dystonia. We have also worked to develop drugs that can be used to assist in the rehabilitation of individuals who abuse cocaine. These studies have provided insights on the role of dopamine and sigma receptors in the brain.
Education/Academic qualification
BA in Chemistry, University of Illinois at Urbana-Champaign
BS in Microbiology, University of Illinois at Urbana-Champaign
PhD in Immunology, University of Pennsylvania
Fingerprint Dive into the research topics where Robert Luedtke is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 2 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
UNTHSC Summer Research Internship Program (SRIP)
Jones, H., Luedtke, R. & Vishwanatha, J.
NIDA: National Institute on Drug Abuse
15/04/18 → 28/02/23
Project: Research
Discovery of Functionally Selective Alzheimer's Disease Therapeutics
NIA: National Institute on Aging
15/09/17 → 31/05/22
Project: Research
Discovery of functionally selective Alzheimer's disease therapeutics
15/08/18 → 31/05/19
Project: Research
Sigma 1 Receptor as a Target for Repetitive Concussive Brain Injury
Schreihofer, D., Luedtke, R. & Sumien, N.
1/08/16 → 30/04/18
Project: Research
Research Output
Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D3 receptor ligands
Chen, P. J., Taylor, M., Griffin, S. A., Amani, A., Hayatshahi, H., Korzekwa, K., Ye, M., Mach, R. H., Liu, J., Luedtke, R. R., Gordon, J. C. & Blass, B. E., 15 Sep 2019, In : Bioorganic and Medicinal Chemistry Letters. 29, 18, p. 2690-2694 5 p.Research output: Contribution to journal › Article
Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs)
Reilly, S. W., Riad, A. A., Hsieh, C. J., Sahlholm, K., Jacome, D. A., Griffin, S., Taylor, M., Weng, C. C., Xu, K., Kirschner, N., Luedtke, R. R., Parry, C., Malhotra, S., Karanicolas, J. & Mach, R. H., 23 May 2019, In : Journal of Medicinal Chemistry. 62, 10, p. 5132-5147 16 p.Research output: Contribution to journal › Article
1
Scopus
citations
Retraction notice to “Dopamine Ds3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors” [Pharmacology, Biochemistry and Behavior 171 (2018) 46–53](S0091305718300236)(10.1016/j.pbb.2018.05.015)
Powell, G. L., Bonadonna, J. P., Vannan, A., Xu, K., Mach, R. H., Luedtke, R. T. & Neisewander, J. L., 1 Jan 2019, In : Pharmacology Biochemistry and Behavior. 176, 1 p.Research output: Contribution to journal › Comment/debate
Analogues of Arylamide Phenylpiperazine Ligands to Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity
Hayatshahi, H. S., Xu, K., Griffin, S. A., Taylor, M., Mach, R. H., Liu, J. & Luedtke, R. R., 19 Dec 2018, In : ACS Chemical Neuroscience. 9, 12, p. 2972-2983 12 p.Research output: Contribution to journal › Article
6
Scopus
citations
Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies
Mach, R. H. & Luedtke, R. T., 1 Mar 2018, In : Journal of Labelled Compounds and Radiopharmaceuticals. 61, 3, p. 291-298 8 p.Research output: Contribution to journal › Article
6
Scopus
citations